| scholarly article | Q13442814 |
| P2093 | author name string | Karl A Nath | |
| Jeffrey L Platt | |||
| Mark D Stegall | |||
| Walter D Park | |||
| Joseph P Grande | |||
| James M Gloor | |||
| Dora Ninova | |||
| P2860 | cites work | Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF. | Q24540358 |
| Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain | Q28142613 | ||
| Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland | Q28208406 | ||
| MUC1, the renaissance molecule | Q28215731 | ||
| Genetically lean mice result from targeted disruption of the RII beta subunit of protein kinase A | Q28507570 | ||
| Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression | Q28594263 | ||
| Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases | Q29547555 | ||
| Transcriptional control by the TGF-beta/Smad signaling system | Q29618985 | ||
| Gene expression during acute allograft rejection: novel statistical analysis of microarray data | Q30755174 | ||
| Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. | Q33949590 | ||
| Signal transduction by tumor necrosis factor and its relatives | Q34341941 | ||
| Autoantibodies in human diabetes | Q34378823 | ||
| Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells | Q35918428 | ||
| Transplantation of discordant xenografts: a review of progress | Q37781951 | ||
| Changes in intragraft gene expression secondary to ischemia reperfusion after cardiac transplantation | Q40625827 | ||
| The GDNF-RET signalling partnership | Q41142426 | ||
| Survival of accommodated cardiac xenografts upon retransplantation into cyclosporine-treated recipients | Q42458175 | ||
| New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis | Q43854449 | ||
| Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. | Q53965909 | ||
| The Banff 97 working classification of renal allograft pathology | Q59314413 | ||
| Accommodation of vascularized xenografts: expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment | Q73034296 | ||
| Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation | Q73212215 | ||
| Anti-HLA antibodies detected in posttransplant renal allograft recipient sera correlate with chronic rejection | Q73279198 | ||
| Donor specific antibody suppression in ABO incompatible kidney transplantation | Q73667796 | ||
| GFR determined by nonradiolabeled iothalamate using capillary electrophoresis | Q73881255 | ||
| Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 | Q74033284 | ||
| Involvement of antibody-dependent apoptosis in graft rejection | Q74052979 | ||
| Expression of human mucin genes in normal kidney and renal cell carcinoma | Q74096498 | ||
| Long-term results of ABO-incompatible living kidney transplantation: a single-center experience | Q74150549 | ||
| Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation | Q74265391 | ||
| Overexpression of MUC1 reconfigures the binding properties of tumor cells | Q77357803 | ||
| Heme oxygenase: protective gene or Trojan horse | Q77658667 | ||
| Renal transplantation across the ABO barrier using A2 kidneys | Q77848896 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| self-injury | Q622527 | ||
| P304 | page(s) | 952-960 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury | |
| P478 | volume | 3 |
| Q51578868 | A Promoter Polymorphism in the CD59 Complement Regulatory Protein Gene in Donor Lungs Correlates With a Higher Risk for Chronic Rejection After Lung Transplantation. |
| Q46545928 | A case of acute humoral rejection with various depositions of C4d, IgG, IgM, and C3c in peritubular capillaries and/or glomerular capillaries |
| Q33280652 | A meta-analysis of kidney microarray datasets: investigation of cytokine gene detection and correlation with rt-PCR and detection thresholds |
| Q38211716 | A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection |
| Q35607565 | ABO Incompatible Kidney Transplantation-Current Status and Uncertainties |
| Q31034921 | ABO incompatible kidney transplantation - an analysis of UNOS Registry data |
| Q28236829 | ABO incompatible renal transplants: Good or bad? |
| Q98771845 | ABO-Incompatible Robotic-Assisted Kidney Transplantation in the Obese Recipient |
| Q51037308 | ABO-incompatible liver transplantation in acute liver failure: a single Portuguese center study. |
| Q37313538 | Accommodation and antibodies |
| Q89137802 | Accommodation in ABO-incompatible organ transplants |
| Q37236857 | Accommodation in organ transplantation |
| Q36902090 | Accommodation of grafts: implications for health and disease |
| Q40108113 | Acute Cellular Rejection and C4d Positivity in Heart Transplantation : A Manifestation of Asymptomatic Antibody-Mediated Rejection? |
| Q37686066 | Advances in immunosuppression for renal transplantation. |
| Q53864549 | Alpha Gal ligation of pig endothelial cells induces protection from complement and apoptosis independently of NF-kappa B and inflammatory changes. |
| Q36263023 | Antibody-mediated organ-allograft rejection |
| Q36443237 | Attitudes toward strategies to increase organ donation: views of the general public and health professionals |
| Q47361584 | C4d and/or immunoglobulins deposition in peritubular capillaries in perioperative graft biopsies in ABO-incompatible renal transplantation |
| Q37042154 | C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts |
| Q37058050 | Chronic alloantibody mediated rejection |
| Q37367683 | Combination of peritubular c4d and transplant glomerulopathy predicts late renal allograft failure. |
| Q38573616 | Complement Interception Across Humoral Incompatibility in Solid Organ Transplantation: A Clinical Perspective |
| Q39718995 | Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates |
| Q36171175 | Current progress in ABO-incompatible kidney transplantation |
| Q98727034 | Current protocols and outcomes of ABO-incompatible kidney transplantation |
| Q47839666 | Defining the phenotype of antibody-mediated rejection in kidney transplantation: Advances in diagnosis of antibody injury |
| Q42872373 | Desensitization and Heart Transplantation of a Patient With High Levels of Donor-Reactive Anti-Human Leukocyte Antigen Antibodies |
| Q86591832 | Desensitization in ABO-Incompatible Kidney Transplantation With Low ABO Iso-Agglutinin Titers |
| Q40815282 | Difference in outcomes after antibody-mediated rejection between abo-incompatible and positive cross-match transplantations |
| Q88581862 | Distribution of Anti-ABO Immunoglobulin G Subclass and C1q Antibody in ABO-incompatible Kidney Transplantation |
| Q34842676 | Economic consequences incurred by living kidney donors: a Canadian multi-center prospective study |
| Q38243366 | Economic evaluation of dialysis therapies |
| Q35547335 | Effect of antibodies on endothelium |
| Q37682997 | Effects of Neutralization by Soluble ABH Antigens Produced by Transplanted Kidneys From ABO-Incompatible Secretor Donors |
| Q35124576 | Emerging role of B cells in chronic allograft dysfunction |
| Q37642331 | Endothelial Cells in Antibody-Mediated Rejection of Kidney Transplantation: Pathogenesis Mechanisms and Therapeutic Implications. |
| Q46915315 | Heart transplantation across the antibodies against HLA and ABO. |
| Q37830813 | Immunohaematological and apheretic aspects of the first kidney transplant from a living, ABO-incompatible donor carried out in Italy |
| Q46908642 | Inhibition of the membrane attack complex of complement for induction of accommodation in the hamster-to-rat heart transplant model |
| Q33319314 | Intragraft gene expression profile associated with the induction of tolerance |
| Q45972317 | Isoagglutinin titre adsorption: breaking the barrier in major AB0-incompatible organ transplantation. |
| Q40477268 | Late and early C4d-positive acute rejection: different clinico-histopathological subentities in renal transplantation. |
| Q35092009 | Late antibody-mediated rejection after ABO-incompatible kidney transplantation during Gram-negative sepsis |
| Q90112402 | Latest insights on ABO-incompatible living-donor renal transplantation |
| Q48165787 | Molecular Assessment of Microcirculation Injury in Formalin-Fixed Human Cardiac Allograft Biopsies With Antibody-Mediated Rejection. |
| Q38172280 | Molecular deciphering of the ABO system as a basis for novel diagnostics and therapeutics in ABO incompatible transplantation |
| Q39466553 | Molecular diagnosis of antibody-mediated rejection in human kidney transplants |
| Q92996524 | New rules of ABO-compatibility in kidney transplantation |
| Q36698811 | Novel insights into lung transplant rejection by microarray analysis |
| Q35565364 | One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allografts |
| Q30544649 | Pros and cons for C4d as a biomarker |
| Q58048128 | Repeat A2 into B kidney transplantation after failed prior A2 into B transplant: A Case Report |
| Q38289602 | Resistance to anti-xenogeneic response by combining alpha-Gal silencing with HO-1 upregulation |
| Q89029586 | Similar Microvascular Inflammation and Tubulointerstitial Injury in ABO-Incompatible and Matched ABO-Compatible Kidney Allografts |
| Q38577657 | Strategies to overcome the ABO barrier in kidney transplantation |
| Q28087773 | The Complement System and Antibody-Mediated Transplant Rejection |
| Q39122863 | The PROCARE consortium: toward an improved allocation strategy for kidney allografts. |
| Q43805381 | The impact of de novo donor-specific anti-human leukocyte antigen antibodies on 5-year renal transplant outcome |
| Q37201483 | The innate immune system and transplantation |
| Q38156510 | The mechanisms of action of plasma exchange. |
| Q58115660 | The multifaceted role of complement in kidney transplantation |
| Q35583534 | The role of B cells and alloantibody in the host response to human organ allografts |
| Q37363951 | The role of antibodies in transplantation |
| Q38013049 | The role of complement in the early immune response to transplantation. |
| Q37952349 | Transplant accommodation--are the lessons learned from xenotransplantation pertinent for clinical allotransplantation? |
| Q42611073 | Upregulation of CD59: potential mechanism of accommodation in a large animal model |
| Q43982164 | Vienna experience of ABO-incompatible living-donor kidney transplantation |
| Q34556780 | Xenotransplantation and ABO incompatible transplantation: the similarities they share |
Search more.